Sema VURAL, Dildar Bahar GENÇ, Serap KARAMAN, Öner DOĞAN, Rejin KEBUDİ

Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma

Background. Chemotherapy with high dose methotrexate is the mainstay of treatment for Burkitt lymphoma (BL), especially to manage central nervous system (CNS) disease. However, methotrexate administration requires close drug level monitoring for appropriate folinic acid rescue, which might not be readily available in all centers. In this study, we assessed the long-term treatment outcomes of a modified Non-Hodgkin lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM) 90 regimen in pediatric high-risk BL without CNS involvement. Methods. Between 1999 and 2011, 42 patients (median age: 7 years) with advanced-stage BL were treated with modified NHL-BFM 90 regimen (methotrexate at a dose of 1 g/m2 ). Demographic data, stage, lactate dehydrogenase (LDH) and treatment results were retrospectively evaluated. The patients were assessed for toxicity, survival and CNS recurrence. Results. Thirty-six patients had Stage III and six had Stage IV disease, respectively. The median LDH level was 1,432 IU/L. Four patients died of infectious and metabolic complications. One patient had local recurrence at the 48th month of the follow-up and he is in the second remission for 72 months. In Kaplan-Meier analysis, the overall survival and event-free survival rates at 10 years were found as 90 % and 88 %, respectively. None of our patients died of treatment failure. Conclusions. The administration of the reduced dose of methotrexate seems to not compromise treatment success nor increase the risk of CNS recurrence in high-risk BL without CNS involvement. The limitation of the study is that it is not randomized. Our treatment scheme might be considered for centers without methotrexate measurement facility

PDF

___

1. Minard-Colin V, Brugieres L, Reiter A, et al. NonHodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol 2015; 27: 2963-2974.

2. Kutluk MT, Yesilipek A. Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Society. Turkish National Pediatric Cancer Registry 2002- 2008 (Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Society. 2013 ASCO Annual Meeting, United States. J Clin Oncol 2013; 31(Suppl 15): 10067.

3. Spreafico F, Massimino M, Luksch R, et al. Intensive, very short-term chemotherapy for advanced Burkitt’s lymphoma in children. J Clin Oncol 2002; 20: 2783-2788.

4. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHLBFM 90. Blood 1999; 94: 3294-3306.

5. Patte C, Auperin A, Michon J, et al; Société Française d’Oncologie Pédiatrique The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.

6. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A. A systematic review and metaanalysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2013; 13: 498-506.

7. Cohen IJ. Progression of osteosarcoma after highdose methotrexate: over-rescue by folinic acid. Pediatr Hematol Oncol 2003; 20: 579-581.

8. Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO). High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 1955-1962.

9. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016; 21: 1471- 1482.

10. Kebudi R, Ayan I, Vural S, Gorgun O, Tokuc G. İleri evre lenfoblastik dışı lenfomada yüksek doz metotreksat içeren BFM-NHL 90 protokolünün sonuçları. Türk Hematoloji-Onkoloji Dergisi 1997; 7: 121-130.

11. World Health Organization. WHO handbook for reporting results of cancer treatment. World Health Organization, 1979. Available at: https://apps.who. int/iris/handle/10665/37200 (Accessed on May 5, 2021).

12. Woessmann W, Seidemann K, Mann G, et al; BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-958.

13. Muller J, Csoka M, Jakab Z, Ponyi A, Erlaky H, Kovacs G. Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols. Pediatr Blood Cancer 2008; 50: 633-635.

14. Buckle G, Maranda L, Skiles J, et al. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: a historical cohort study. Int J Cancer 2016; 139: 1231-1240.

15. Stanley CC, Westmoreland KD, Heimlich BJ, et al. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. Br J Haematol 2016; 173: 705-712.

16. Celkan TT, Baris S, Ozdemir N, et al. Treatment of pediatric Burkitt lymphoma in Turkey. J Pediatr Hematol Oncol 2010; 32: e279-e284.

17. Karadeniz C, Oguz A, Citak EC, et al. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol 2007; 24: 417-430.

18. Kebudi R, Zulfikar B, Cakır FB, et al. Non-Hodgkin lymphoma in children: Is 1 g/m2 methotrexate as effective as 5 g/m2 in advanced-stage nonlymphoblastic non-Hodgkin lymphoma? J Clin Oncol 2013; 31(Suppl 15): 10043.

19. Vural S, Kebudi R, Akıcı F, et al. Results of the modified BFM-NHML 90 chemotherapy regimen in children with advanced stage nonlymphoblastic lymphoma. Med Pediatr Oncol 2003; 41: 254.

20. Klumb CE, Schramm MT, De Resende LM, et al. Treatment of children with B-cell non-Hodgkin’s lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol 2004; 26: 462-468.

21. Moleti ML, Al-Hadad SA, Al-Jadiry MF, et al. Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. Pediatr Blood Cancer 2011; 56: 560-567.

22. Acquatella G, Insausti CL, Garcia R, et al. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol. Pediatr Blood Cancer 2004; 43: 580-586.

23. Meremikwu MM, Ehiri JE, Nkanga DG, Udoh EE, Ikpatt OF, Alaje EO. Socioeconomic constraints to effective management of Burkitt’s lymphoma in south-eastern Nigeria. Trop Med Int Health 2005; 10: 92-98.

24. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent nonHodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 2007; 25: 3915-3922.

25. Woessmann W, Seidemann K, Mann G, et al; BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-958.

26. Kavan P, Kabickova E, Gajdos P, et al. Treatment of children and adolescents with non-Hodgkin’s lymphoma (results based on the NHL BerlinFrankfurt-Munster 90 protocols). Cas Lek Cesk 1999; 138: 40-46.

27. Müller J, Csóka M, Jakab Z, Ponyi A, Erlaky H, Kovács G. Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols. Pediatr Blood Cancer 2008; 50: 633-635.

28. Pillon M, Di Tullio MT, Garaventa A, et al. Longterm results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101: 385- 394.

29. Sun XF, Zhen ZJ, Lui DG, et al. Improved treatment outcome in Chinese children and adolescents with Burkitt’s lymphoma and large cell lymphoma by using the modified B-non-Hodgkin’s lymphomaBerlin-Frankfurt-Münster-90 protocol. Eur J Haematol 2006; 77: 365-371.

30. Cervio C, Barsotti D, Ibanez J, Paganini H, Sara Felice M, Chantada GL. Early mortality in children with advanced mature B-cell malignancies in a middleincome country. J Pediatr Hematol Oncol 2012; 34: e266-e270.

31. Chantada G, Casak S, Alderete D, Zubizarreta P, Gallo G, Muriel FS. Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina. Med Pediatr Oncol 2003; 41: 488-490.

32. Márky I, Björk O, Forestier E, et al; Nordic Society of Pediatric Hematology and Oncology. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the Nordic Society of Pediatric Hematology and Oncology. J Pediatr Hematol Oncol 2004; 26: 555-560.

33. Dokmanovic L, Krstovski N, Vukanic D, et al. Pediatric non-Hodgkin lymphoma: a retrospective 14-year experience with Berlin-Frankfurt-Münster (BFM) protocols from a tertiary care hospital in Serbia. Pediatr Hematol Oncol 2012; 29: 109-118.

34. Samochatova EV, Maschan AA, Shelikhova LN, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol 2014; 36: 395-401.